Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.60 |
| ▸ | KIF11 | P52732 | 4/20 | 0.50 |
| ▸ | CASR | P41180 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18014703 | 0.88 | MAOB (0.50) | AGXTMAOB | |
| SCHEMBL197793 | 0.84 | GGPS1 (0.44) | AGXTGGPS1 | |
| SCHEMBL20782328 | 0.83 | MAOB (0.60) | AGXTKIF11MAOBPTPN5 | |
| SCHEMBL13182829 | 0.83 | AGXT (0.60) | AGXTKIF11CASRMAOBPTPN5 | |
| SCHEMBL14357376 | 0.83 | AGXT (0.56) | AGXTPTPN5MGLLGGPS1 | |
| SCHEMBL257786 | 0.83 | AGXT (0.64) | AGXTKIF11CASRMAOBPTPN5 | |
| SCHEMBL20781935 | 0.82 | KIF11 (0.54) | KIF11MAOB | |
| SCHEMBL73993 | 0.80 | HTR2A (0.58) | MAOB | |
| SCHEMBL18014710 | 0.80 | KIF11 (0.53) | KIF11FFAR1 | |
| SCHEMBL894079 | 0.79 | AGXT (0.69) | AGXTKIF11CASRMAOBPTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | AGXT 4198/4885KIF11 4539/4885CASR 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.